Table 2.
Reported effect on lipid parameters in mineral oil placebo groups from non-CV disease and diabetes studies
| Author | n a | Dose and mineral oil used | Patient population | Statins | Duration of treatment | TG | LDL-C | Non–HDL-C | HDL-C |
|---|---|---|---|---|---|---|---|---|---|
| De Truchis et al.,45 2007 | 62 | 2 g/day, paraffin oil | HIV patients on antiviral therapy; BL TG >200 mg/dL and <1000 mg/dL | Patients taking lipid-lowering drugs excluded | 8 weeks | +6.4% | NR | NR | +8.08% |
| Horrobin et al.,46 1991 | 10 | 4 g/day over 7 days, liquid paraffin | Healthy adults | NR | 10 days | No change | NR | NR | NR |
| Lemos et al.,47 2012 | 60 | 2 g/day, mineral oil | Terminal renal failure undergoing chronic haemodialysis | NR | 120 days | +12.5% | −6.1% | NR | +1.7% |
| Emsley et al.,48 2008 | 33 | 2 g/day, medicinal liquid paraffin | Schizophrenia or schizoaffective disorder and coexistent tardive dyskinesia | NR | 12 weeks | −13.3% | 0% | NR | −7.1% |
| Fogaça et al.,49 2011 | 11 | NA, paraffin | Alcohol-dependent patients | NR | 90 days | NR | NS | NR | NS |
| Mohammadi et al.,50 2012 | 31 | 2 g/day, liquid paraffin | Women with polycystic ovary syndrome | NR | 8 weeks | −4.8% | 0% | NR | −0.9% |
| Peet and Horrobin,51 2002 | 6 | 4 g/day; liquid paraffin | Schizophrenia; all six patients on clozapine | NR | 12 weeks | +15.8% | NR | NR | NR |
| Yang et al.,52 1999 | 18 | 5 g/day, paraffin oil | Atopic dermatitis | NR | 1 month | −1.8% | +2.4% | NR | +3.6% |
| 4 months | 0% | +1.0% | +6.4% | ||||||
| Nogueira et al.,53 2016 | 28 | 4 mL/day, mineral oil | Non-alcoholic steatohepatitis | NR | 6 months |
BL: 148.6 mg/dL EOT: NR P = NS |
BL: 116.6 mg/dL EOT: NR P = NS |
NR |
BL: 52.1 mg/dL EOT: NR P = NS |
| Allain et al.,54 2009 | 8 | 3 g/day, paraffin oil | Healthy volunteers | NR | 6 weeks | No significant change | No significant change | NR | No significant change |
| Mirmasoumi et al.,55 2018 | 30 | 1 g/day, liquid paraffin | Polycystic ovary syndrome | NR | 12 weeks | +8.6% | +3.1% | +1.9% | |
| Paixao et al.,56 2017 | 22 | 2 g/day, mineral oil | Breast cancer patients | NR | 30 days | −16% | −3.1% | NR | +2.1% |
| Mejia-Montilla et al.,57 2018 | 85 | Mineral oil capsule | Women with polycystic ovary syndrome and vitamin D deficiency | NR | 12 weeks | +0.8% | +1.7% | NR | −3.4% |
| Ghorbanihaghjo et al.,58 2012 | 43 | 1 g, paraffin pearl in the fasted state | Adult females diagnosed with RA and on a fixed therapeutic schedule for ≥2 months before study entry | Patients taking lipid-lowering drugs excluded | 3 months | NR | NR | NR |
BL: 38.6 mg/dL EOT: 38.2 mg/dL |
| Kremer et al.,59 1985 | 21 | 1.8 g/day, non-digestible paraffin wax | Rheumatoid arthritis | NR | 12 weeks | +18.5% | NR | NR | NR |
| Ferreira et al.,60 2019 | 80 | 5 oral drops of placebo (1% powdered lemon flavour, 0.2% ethylene-diamine- tetraacetic acid, liquid flavour qs, and liquid petrolatum qsp in 20 mL) | Post-menopausal women aged 50–65 years | NR | 9 months | +1.6% | −2.2% | NR | −0.4% |
| Rashidmayvan et al.,61 2019 | 22 | 1 g/day, paraffin oil | Patients aged 20–60 years with non-alcoholic fatty liver disease | NR | 8 weeks | −1.0% | −1.0% | NR | +1.7% |
BL, baseline; CV, cardiovascular; EOT, end of treatment; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NR, not reported; NS, not significant; TG, triglycerides.
a
Number of participants in the mineral oil placebo group.